CLSA Events

Life Science Series: A Delicate Balance Partnering to Optimize, Not Impair, Company Value

In collaboration with

Latham & Watkins

Corporate partnering transactions allow life sciences companies to fund product development activities, obtain necessary expertise, validate technology and products and create and expand product markets. However, these transactions can also impose significant restrictions on the licensor’s business by operation of terms such as exclusive licenses, exclusivity covenants, change of control provisions, options and rights of refusal. These restrictions can, if not structured carefully, result in a licensor having limited or no ability to expand its technology platform or product pipeline, and significantly impair the value of the company to a potential acquirer. The panel will discuss strategies for partnering while retaining sufficient rights to grow a life sciences company’s business, attract potential acquirers and optimize company value in a potential acquisition.

Moderator

Alan C. Mendelson
Senior Partner, Latham & Watkins

Panel Speaker

Tassos Gianakakos
Senior VP
Corp and Business Development
MAP Pharmaceuticals, Inc.

Kathleen Sereda Glaub
President & CFO
Plexxikon

Camille Samuels
Managing Director
Versant Ventures

What: Life Science Series:
A Delicate Balance
Partnering to Optimize, Not Impair,
Company Value
When: Tuesday, April 24, 2012
Registration: 8:00AM – 9:00AM
Breakfast, Networking: 8:00AM – 8:30AM
Program: 8:30AM – 10:00AM
Networking: 10:00AM – 10:30AM
Where: Latham & Watkins
140 Scott Drive
Menlo Park, California 94025
Directions
Cost: Pre-registration through April 22
$20 members
$40 non-members
On-site registration on April 24
$40 members
$80 non-members
Attire: Business attire suggested